Raw sequencing data were deposited to the European Nucleotide Archive repository under accession number PRJEB36810.

Introduction {#sec001}
============

In many invertebrate host-pathogen systems, infection success depends on the specific pairing of host and pathogen genotypes \[[@pgen.1008794.ref001]\]. Such genotype-by-genotype (G x G) interactions have been observed, for example, between crustaceans and bacteria \[[@pgen.1008794.ref002]\], bumblebees and intestinal trypanosomes \[[@pgen.1008794.ref003]\], nematodes and bacteria \[[@pgen.1008794.ref004]\], anopheline mosquitoes and malaria parasites \[[@pgen.1008794.ref005], [@pgen.1008794.ref006]\] and butterflies and protozoan parasites \[[@pgen.1008794.ref007]\]. In some instances, G x G interactions can result in extreme levels of host-pathogen specificity \[[@pgen.1008794.ref008]\].

Understanding this genetic specificity in invertebrate host-pathogen systems has generated great enthusiasm because it may uncover new facets of invertebrate immunity \[[@pgen.1008794.ref009], [@pgen.1008794.ref010]\]. Although invertebrates lack the adaptive immunity of vertebrates, their immune system can generate a considerable diversity of immune receptors, revealing an unsuspected molecular complexity \[[@pgen.1008794.ref011], [@pgen.1008794.ref012]\]. Alternatively, G x G interactions could be mediated by variation in the host microbiota \[[@pgen.1008794.ref013]\] or any other interplay between host and pathogen genomes. G x G interactions can be detected at the level of gene expression \[[@pgen.1008794.ref014]\] and mapped to physical locations in the host genome \[[@pgen.1008794.ref015]--[@pgen.1008794.ref017]\]. Accumulating observations on G x G interactions have led to some controversy \[[@pgen.1008794.ref018]--[@pgen.1008794.ref020]\] because they challenge the prevailing view that invertebrate defense against pathogens relies on broad-spectrum recognition and effector mechanisms. A central aspect of the controversy is that the molecular mechanisms underlying G x G interactions between invertebrate hosts and pathogens are yet to be elucidated.

We previously documented significant G x G interactions between dengue virus (DENV) and its main mosquito vector *Aedes aegypti* \[[@pgen.1008794.ref021], [@pgen.1008794.ref022]\]. Both DENV and *Ae*. *aegypti* are genetically diverse in nature. DENV exists worldwide as four genetic types (DENV-1, DENV-2, DENV-3, and DENV-4) that loosely cluster antigenically \[[@pgen.1008794.ref023]\] and are often referred to as serotypes. The mosquito *Ae*. *aegypti* consists of two major genetic subspecies that contain substantial genetic diversity \[[@pgen.1008794.ref024]\]. In the last few decades, DENV has become a major public health threat worldwide with an estimated 390 million human infections per year \[[@pgen.1008794.ref025]\]. The lack of an efficient vaccine and the failure of insecticide-based methods to control mosquito populations on the long term have stimulated basic research to develop novel vector control strategies \[[@pgen.1008794.ref026]\]. One of these strategies aims at rendering mosquitoes resistant to pathogen infection \[[@pgen.1008794.ref027]\]. The premise of this strategy makes it critical to understand G x G interactions because engineered mosquito resistance should be effective against all possible pathogen genotypes.

Dissecting the genetic basis of G x G interactions between DENV and *Ae*. *aegypti* was previously hampered by the large size of the *Ae*. *aegypti* genome and the paucity of genetic markers available \[[@pgen.1008794.ref028]\]. Although G x G interactions between DENV and *Ae*. *aegypti* were statistically assigned to individual mosquito genetic markers \[[@pgen.1008794.ref015], [@pgen.1008794.ref017]\], the specific mosquito genes underlying these quantitative trait loci (QTL) have not been identified. In particular, it is unknown whether DENV type- or strain-specific resistance relies on allelic variants of the same genes or on distinct gene sets.

Here, we combined a natural phenotype of DENV type-specific resistance in *Ae*. *aegypti* and the power of high-throughput sequencing to provide insights into the genetic architecture of G x G interactions in this system. We previously established a laboratory colony from a wild *Ae*. *aegypti* population in Bakoumba, Gabon that is differentially susceptible to DENV types. Using dose-response experiments, we found the Bakoumba population to be strongly resistant to DENV-1 and only moderately resistant to DENV-3 infection. We took advantage of this field-derived colony to investigate the genetic basis for discriminating between different DENV types. We used a modified genome-wide association study design, in which replicate pools of individuals with contrasted phenotypes are pooled by phenotype and analyzed for differences in allele frequencies \[[@pgen.1008794.ref029], [@pgen.1008794.ref030]\]. We compared the genetic basis of Bakoumba resistance to DENV-1 and DENV-3 from extremes of the phenotypic distribution (i.e., resistant = uninfected at a high virus dose vs. susceptible = infected at a low virus dose). We estimated and compared allele frequencies among the phenotypic pools using the contrast statistic recently implemented in the software BayPass \[[@pgen.1008794.ref031], [@pgen.1008794.ref032]\]. Because the genome of *Ae*. *aegypti* is large and repetitive, we performed exome sequencing as a cost-effective genotyping method targeting the exons of all protein-coding genes \[[@pgen.1008794.ref033]\], as was previously implemented in *Ae*. *aegypti* \[[@pgen.1008794.ref034]--[@pgen.1008794.ref036]\]. We combined SNP-specific contrasts of allele frequency to compute gene-wide scores reflecting the statistical significance of association with DENV-1 and/or DENV-3 infection. The results of our exome-wide association study (EWAS) show that largely distinct gene sets underlie specific resistance to DENV-1 and DENV-3 infection in this *Ae*. *aegypti* population.

Results {#sec002}
=======

Dose-response experiments {#sec003}
-------------------------

We initially compared the infection dose response of two outbred *Ae*. *aegypti* colonies from Cairns (Australia) and Bakoumba (Gabon) following oral exposure to either DENV-1 or DENV-3. In two separate experiments, female mosquitoes from both colonies were offered artificial blood meals containing one of three increasing infectious doses ranging from 1.0 x 10^4^ to 3.3 x 10^7^ FFUs/mL for DENV-1 and from 1.0 x 10^4^ to 3.9 x 10^7^ FFUs/mL for DENV-3 ([Fig 1A](#pgen.1008794.g001){ref-type="fig"}). Ten days after virus exposure, infection status was determined by RT-PCR for 24--32 (mean 30.8; median 32) blood-fed females for each combination of experiment, population, virus and dose. In total, 366 individual females were tested for DENV-1 and 374 individual females were tested for DENV-3. As expected, infectious dose was a significant predictor of infection prevalence ([Table 1](#pgen.1008794.t001){ref-type="table"}). In addition, we observed a strong pattern of G x G interactions, whereby the Bakoumba population was significantly more resistant to DENV-1 than the three other population-virus combinations ([Fig 1A](#pgen.1008794.g001){ref-type="fig"}). This G x G interaction was statistically supported by a significant effect (*p* = 0.0013) of the population x virus interaction on the infection phenotype ([Table 1](#pgen.1008794.t001){ref-type="table"}). Based on the regression curves of the combined dose responses, we estimated that the 50% oral infectious doses (OID~50~) of the Bakoumba population were 7.08 log~10~ FFUs/mL (95% confidence interval: 6.84--7.44) for DENV-1 and 5.54 log~10~ FFUs/mL (95% CI: 5.23--5.80) for DENV-3. The OID~50~ estimates of the Cairns population were 5.80 log~10~ FFUs/mL (95% CI: 5.58--6.00) for DENV-1 and 5.01 log~10~ FFUs/mL (95% CI: 4.68--5.26) for DENV-3. The dose-response analysis showed that the Bakoumba population was intrinsically more resistant to DENV-1 than to DENV-3 infection, although the DENV-1 and DENV-3 isolates were equally infectious to the mosquito population from Cairns. In the rest of the study, we took advantage of this natural resistance phenotype to dissect the genetic architecture of DENV type-specific resistance in *Ae*. *aegypti*. A direct comparison between the Bakoumba and the Cairns populations would be impractical because their genetic differentiation would likely mask any loci underlying DENV resistance that are shared or divergent between them. Indeed, the Bakoumba population presumably belongs to the African subspecies, *Ae*. *aegypti formosus*, whereas the Cairns population presumably belongs to the globally invasive subspecies, *Ae*. *aegypti aegypti*, therefore the two populations are expected to be genetically divergent \[[@pgen.1008794.ref024]\]. In contrast, the comparison between phenotypically resistant or susceptible individuals within the Bakoumba population allowed us to control for the genetic background.

![Investigating the DENV type-specific resistance phenotype of Bakoumba mosquitoes.\
(**A**) Dose-response curves of *Ae*. *aegypti* colonies from Bakoumba (Gabon) or Cairns (Australia) challenged with DENV-1 and DENV-3. The percentage of DENV-infected mosquitoes at 10 days post exposure is shown as a function of the blood meal titer in log~10~-transformed focus-forming units (FFUs)/mL. The data was obtained in two separate dose-response experiments with three doses for each virus. The three doses of experiment 1 are covering a lower range than the three doses of experiment 2. Curves are logistic regressions of the data with their 95% confidence intervals indicated by shaded bands. Note that one data point (Bakoumba DENV-3 experiment 2) is masked due to the overlap with another value at 100% (Cairns DENV-3 experiment 2). (**B**) Experimental design for the exome-wide association analysis (EWAS) of DENV type-specific resistance of Bakoumba mosquitoes. Female mosquitoes of the Bakoumba population were exposed to low and high infectious doses of DENV-1 and DENV-3, expected to result in about one third and two thirds of infected mosquitoes, respectively. Bodies were used to screen for infection status by RT-PCR, and heads were collected for DNA extraction and exome sequencing. The EWAS analysis compared pools of individuals that were uninfected at the high dose (i.e., resistant) versus individuals infected at the low dose (i.e., susceptible) for each DENV type.](pgen.1008794.g001){#pgen.1008794.g001}

10.1371/journal.pgen.1008794.t001

###### Test statistics of the DENV dose-response analysis.

Infection prevalence was analyzed by logistic regression as a function of replicate experiment, dose, population, virus, and all their interactions. The table shows the minimal adequate model after sequentially removing non-significant effects. Oral infectious dose (blood meal titer) was log~10~-transformed prior to the analysis.

![](pgen.1008794.t001){#pgen.1008794.t001g}

  Source               Df   L-R χ^2^   *P* value
  -------------------- ---- ---------- -----------
  Experiment           1    9.882      0.0017
  Dose                 1    290.8      \<0.0001
  Population           1    64.79      \<0.0001
  Virus                1    87.90      \<0.0001
  Population x Virus   1    10.39      0.0013

Df = degrees of freedom; L-R = likelihood-ratio.

Exome-wide association study {#sec004}
----------------------------

We reasoned that if Bakoumba mosquitoes were intrinsically more resistant to DENV-1 than to DENV-3 infection, the genetic factors underlying resistance to each DENV type would be distinct. Our study was designed to determine whether DENV type-specific resistance in the Bakoumba population relied on different alleles of the same genes (i.e., if a DENV-1 resistance allele also confers susceptibility to DENV-3) or on genetic variation at distinct gene sets (i.e., if DENV-1 resistance and susceptibility alleles do not influence DENV-3 infection). To identify allelic variants associated with both DENV-1 and DENV-3 resistance or susceptibility, we sequenced the exome of four phenotypic pools of Bakoumba mosquitoes ([Fig 1B](#pgen.1008794.g001){ref-type="fig"}): DENV-1 resistant (i.e., uninfected after exposure to a high DENV-1 dose), DENV-1 susceptible (i.e., infected after exposure to a low DENV-1 dose), DENV-3 resistant (i.e., uninfected after exposure to a high DENV-3 dose), and DENV-3 susceptible (i.e., infected after exposure to a low DENV-3 dose). Low and high infectious doses were adjusted to result in approximately one third and two thirds of infected mosquitoes, respectively. Due to the difference in the dose responses ([Fig 1A](#pgen.1008794.g001){ref-type="fig"}), low and high infectious doses were different for each DENV type ([Table 2](#pgen.1008794.t002){ref-type="table"}). DNA was extracted from the head tissues of each individual mosquito whereas the infection phenotype was determined by RT-PCR testing of the head-less mosquito body 10 days post infectious blood meal. The phenotypic screen was performed in three replicate experiments.

10.1371/journal.pgen.1008794.t002

###### Infectious doses used for the EWAS phenotypic screen.

The table shows the measured titer of DENV-1 and DENV-3 infectious blood meals for each of the three experimental replicates of the exome-wide association study in the Bakoumba population.

![](pgen.1008794.t002){#pgen.1008794.t002g}

  Experiment   Virus          Dose           Titer (FFUs/mL)
  ------------ -------------- -------------- -----------------
  Exp. 1       DENV-1         High           1.00 x 10^7^
  Low          1.26 x 10^6^                  
  DENV-3       High           7.75 x 10^5^   
  Low          7.25 x 10^4^                  
  Exp. 2       DENV-1         High           1.10 x 10^7^
  Low          8.75 x 10^5^                  
  DENV-3       High           9.13 x 10^5^   
  Low          4.88 x 10^4^                  
  Exp. 3       DENV-1         High           8.63 x 10^6^
  Low          9.50 x 10^5^                  
  DENV-3       High           4.75 x 10^5^   
  Low          5.25 x 10^4^                  

FFU = focus-forming unit

Association analyses at the single-nucleotide level {#sec005}
---------------------------------------------------

The bodies of 668, 690 and 680 females was individually tested for DENV infection by RT-PCR in replicate experiments 1, 2 and 3, respectively ([Table 3](#pgen.1008794.t003){ref-type="table"}). Based on their resistant or susceptible phenotype, 182, 174 and 176 females were selected for DNA extraction from experiments 1, 2 and 3, respectively. DNA extracted from the head of individual females was combined into 12 phenotypic pools (3 experiments x 2 DENV types x 2 phenotypes) of 30--48 individuals (mean 44.3) to prepare 12 libraries for exome sequencing ([Table 3](#pgen.1008794.t003){ref-type="table"}). Individual DNA concentrations were adjusted prior to pooling so that each individual contributed the same amount of DNA to the library. Across all three chromosomes, a total of approximately 1.4 million SNPs were identified with an average sequencing depth ranging from 100.6X to 176.4X (mean 132.7X) among the 12 libraries. We first performed association analyses at the level of individual SNPs based on allele frequency differences between DENV-1 resistant and susceptible pools (DENV-1 comparison) and between DENV-3 resistant and susceptible pools (DENV-3 comparison). For both the DENV-1 and the DENV-3 comparisons, the largest number of significant SNPs was detected on chromosome 1 but each DENV type displayed a distinct profile ([S1A Fig and S1B Fig](#pgen.1008794.s001){ref-type="supplementary-material"}). Among the top 0.001% most significant SNPs for each comparison, 5 SNPs were shared between the DENV-1 and DENV-3 comparisons, 142 were uniquely associated with DENV-1 infection status, and 146 were uniquely associated with DENV-3 infection status ([S1 Table](#pgen.1008794.s003){ref-type="supplementary-material"}; [S1C Fig](#pgen.1008794.s001){ref-type="supplementary-material"}). For the 5 shared SNPs, allelic effects were in the same direction (i.e., the same allele was associated with both DENV-1 and DENV-3 resistance).

10.1371/journal.pgen.1008794.t003

###### Summary of mosquitoes analyzed for each experimental replicate of the EWAS phenotypic screen.

The table shows the number of Bakoumba mosquitoes that tested DENV-positive or DENV-negative by RT-PCR ([S2 Fig](#pgen.1008794.s002){ref-type="supplementary-material"}) in each of the experimental conditions of the screen. Cells highlighted in yellow are experimental conditions used as opposite phenotypes for the exome-wide association study. The number shown in brackets represents the number of mosquitoes selected for DNA extraction and subsequent sequencing.
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  Experiment   Virus    Dose   Infection prevalence   Number infected   Number uninfected   Total analyzed
  ------------ -------- ------ ---------------------- ----------------- ------------------- ----------------
  Exp. 1       DENV-3   Low    27%                    42 (41)           116                 158
  DENV-3       High     59%    83                     58 (48)           141                 
  DENV-1       Low      38%    70 (48)                116               186                 
  DENV-1       High     75%    138                    45 (45)           183                 
  Exp. 2       DENV-3   Low    34%                    64 (48)           124                 188
  DENV-3       High     65%    117                    62 (48)           179                 
  DENV-1       Low      36%    63 (48)                110               173                 
  DENV-1       High     80%    120                    30 (30)           150                 
  Exp. 3       DENV-3   Low    26%                    47 (45)           135                 182
  DENV-3       High     67%    117                    57 (48)           174                 
  DENV-1       Low      57%    85 (48)                63                148                 
  DENV-1       High     80%    141                    35 (35)           176                 

Association analyses at the gene level {#sec006}
--------------------------------------

To identify candidate genes associated with DENV-1 and/or DENV-3 infection status, we performed a second series of association analyses based on an average score calculated for each annotated gene. An empirical *p* value was computed from the average gene scores adjusted for differences in SNP count per gene. Note that although the exome capture probes were designed using the AaegL3 genome build \[[@pgen.1008794.ref028]\] because it was the only one available at the time, our gene-based analysis was performed using the more recent AaegL5 genome build \[[@pgen.1008794.ref017]\], which is significantly better annotated. Of the 19,763 genes annotated in the AaegL5 reference sequence, our exome capture probes covered 11,076 genes. Overall, the chromosomal distribution of empirical *p* values computed for each gene and each DENV type ([Fig 2](#pgen.1008794.g002){ref-type="fig"}) was consistent with the pattern observed with the SNP-based analysis ([S1 Fig](#pgen.1008794.s001){ref-type="supplementary-material"}). The most significant genes were detected on chromosome 1 around the centromere for both DENV types. Although there are regions of similarity between the DENV-1 and DENV-3 comparisons, the genetic architecture underlying DENV-1 and DENV-3 infection phenotypes is markedly distinct ([Fig 2](#pgen.1008794.g002){ref-type="fig"}). Among the top 5% most significant candidate genes for each DENV type, 287 genes are uniquely associated with DENV-1 infection status, 290 are uniquely associated with DENV-3 infection status, and 263 genes are shared ([S2 Table](#pgen.1008794.s004){ref-type="supplementary-material"}; [Fig 3A](#pgen.1008794.g003){ref-type="fig"}).

![Genes associated with DENV-1 and DENV-3 infection in the Bakoumba population.\
**(A)** Manhattan plot of empirical *p* values derived from average gene scores of DENV-1 resistance, distributed along the three chromosomes. The gene scores reflect variation in SNP frequencies (adjusted for differences in SNP counts) between phenotypic pools of mosquitoes that are either resistant of susceptible to DENV-1. **(B)** Manhattan plot of empirical *p* values derived from average gene scores of DENV-3 resistance, distributed along the three chromosomes. The gene scores reflect variation in SNP frequencies (adjusted for differences in SNP counts) between phenotypic pools of mosquitoes that are either resistant of susceptible to DENV-3. Each dot represents a single gene and is colored according to the statistical significance of the genotype-phenotype association. Blue dots represent the lower 5% of *p* values and red dots represent the lower 2.5% *p* values.](pgen.1008794.g002){#pgen.1008794.g002}

![Limited overlap between genes associated with DENV-3 or DENV-1 infection in the Bakoumba population.\
(**A**) Venn diagram of the 5% most significant genes associated with resistance to DENV-1, resistance to DENV-3, or both. (**B**) TreeMap visualization of molecular function enrichment for the 5% most significant genes. Each first level category is represented by a large rectangle filled with nested rectangles corresponding to the GO term annotation. The size of the rectangle is proportional to the number of genes in the list out of the total number of genes with similar roles in the *Ae*. *aegypti* genome. Bold font represents a higher category level.](pgen.1008794.g003){#pgen.1008794.g003}

Finally, we sought to determine whether the 5% most significant genes in the gene-based analysis belonged to different functional categories. We focused on the molecular mechanisms potentially underlying DENV type-specific resistance and accordingly we extracted gene ontology (GO) terms that exhibited a significant enrichment in the molecular function category. The 290 genes uniquely associated with resistance to DENV-3 infection were enriched in genes with zinc ion binding activity ([Fig 3B](#pgen.1008794.g003){ref-type="fig"}). The 287 genes uniquely associated with resistance to DENV-1 were not significantly enriched in any particular molecular function. The 263 genes shared between the two comparisons were enriched in genes with ATP binding activity and sulfur compound transmembrane transporter activity ([Fig 3B](#pgen.1008794.g003){ref-type="fig"}).

Discussion {#sec007}
==========

Our EWAS revealed that the DENV type-specific resistance phenotype displayed by an *Ae*. *aegypti* population from Bakoumba, Gabon reflects a distinct genetic architecture of resistance to DENV-1 and DENV-3 infection. The midgut infection phenotype we focused on is an important component of vector competence, which also depends on subsequent virus dissemination from the midgut and virus release in saliva \[[@pgen.1008794.ref037]\]. We unveiled a set of SNPs and genes that are significantly associated with DENV-1 and/or DENV-3 infection in the Bakoumba population, which open the way to future studies to functionally characterize the genetic basis of DENV type-specific resistance. The overlap between SNPs and genes associated with resistance to either DENV-1 or DENV-3 was only partial and demonstrated that DENV type-specific resistance relies on both shared and unique genes in this *Ae*. *aegypti* population. Although the mechanisms of DENV type-specific resistance in *Ae*. *aegypti* remain to be elucidated, this study is a leap forward to understand G x G specificity between *Ae*. *aegypti* and DENV at the molecular level.

G x G specificity between pathogens and their invertebrate hosts has been observed in many systems \[[@pgen.1008794.ref001]\], but to date the molecular nature of this specificity is largely unknown. We previously detected G x G interactions between DENV and *Ae*. *aegypti* \[[@pgen.1008794.ref021], [@pgen.1008794.ref022]\] that could be statistically associated with QTL in the mosquito genome \[[@pgen.1008794.ref015], [@pgen.1008794.ref017]\]. However, the specific mosquito genes underlying these QTL have not been identified. One important question to elucidate the genetic basis of host-pathogen specificity is whether pathogen genotype-specific resistance relies on different alleles or different genes of the host. In the "matching-allele" model of host-pathogen interactions, a resistant allele against a given pathogen strain becomes a susceptible allele against another strain of the same pathogen \[[@pgen.1008794.ref038]\]. This was observed, for example, by experimental viral evolution to specific mouse MHC genotypes \[[@pgen.1008794.ref039]\] and by genetic crosses between genotypes of the crustacean *Daphnia magna* with different levels of resistance to the parasitic bacterium *Pasteuria ramosa* \[[@pgen.1008794.ref040], [@pgen.1008794.ref041]\]. In other host-pathogen systems, host resistance to different strains of the same pathogen relies on allelic variation at different genes. For example, genome-to-genome analysis of associations between human genetic variation and HIV-1 sequence found SNPs in different HLA class I genes \[[@pgen.1008794.ref042]\]. Likewise, *Arabidopsis thaliana* SNPs exhibited genetic effects only when paired with certain *Xanthomonas arboricola* variants \[[@pgen.1008794.ref043]\]. In the mosquito *Anopheles gambiae*, discrimination between human and rodent malaria species was shown to rely on different paralogs of the APL1 gene family \[[@pgen.1008794.ref044]\]. Resistant and susceptible alleles of the TEP1 gene of *An*. *gambiae* explained resistance to some but not all strains of the human malaria parasite *Plasmodium falciparum* \[[@pgen.1008794.ref045], [@pgen.1008794.ref046]\].

We took advantage of the striking DENV type-specific phenotype of our Bakoumba *Ae*. *aegypti* colony to use it as a simplified model of G x G interactions that could be subjected to a genetic association study. Note that in this study, we focused on the host factors involved in the G x G interaction but the virus factors remain to be elucidated. We found that in the Bakoumba population, about half of the genes associated with resistance to DENV-1 infection did not confer resistance to DENV-3 infection and vice versa. Whether the genetic architecture of DENV type-specific resistance in the Bakoumba population is representative of G x G interactions between *Ae*. *aegypti* and DENV, and in other invertebrate host-pathogen systems in general, is unknown. Additional work will be necessary to extend these results to other mosquito populations, other DENV types and strains, and other host-pathogen systems. Moreover, our association study focused on the discovery of SNPs in exons, which represent only about 2% of the entire *Ae*. *aegypti* genome \[[@pgen.1008794.ref017], [@pgen.1008794.ref028]\]. It is possible that our exome-sequencing approach may have missed important genetic determinants underlying DENV type-specific resistance because they are not readily detected by SNPs (e.g., structural variants) and/or they occur in introns or intergenic regions. As sequencing technologies become more affordable, whole-genome sequencing will allow more comprehensive surveys of genetic variation in the *Ae*. *aegypti* genome. Nevertheless, detection of different exome variants associated with resistance to DENV-1 and resistance to DENV-3 is sufficient to support our conclusion that their respective genetic architecture is distinct.

It is worth noting that regardless of the biases introduced by exome sequencing, these biases are consistent across experimental conditions. In other words, comparing the genetic basis of resistance to DENV-1 infection to the genetic basis of resistance to DENV-3 infection remains valid despite shortcomings in the genotyping method, because it was performed with the same initial population. Our finding that only about one third of the top 5% genes was jointly associated with both DENV-1 resistance and DENV-3 resistance cannot be explained by differences in genetic ascertainment because for both DENV types the genes were identified with the same set of SNPs in the same population.

The bulk of significant SNPs and genes were found on chromosome 1, particularly around the centromere. This observation could be due to at least two, non-mutually exclusive explanations. First, most of the genetic loci underlying DENV susceptibility in the Bakoumba population could be truly located on chromosome 1. QTL associated with DENV susceptibility in *Ae*. *aegypti* were previously detected on all three chromosomes \[[@pgen.1008794.ref015], [@pgen.1008794.ref017], [@pgen.1008794.ref047], [@pgen.1008794.ref048]\], and the genetic architecture of pathogen susceptibility is known to vary across host populations \[[@pgen.1008794.ref049]\]. Second, the centromeric region of chromosome 1 contains the M locus responsible for sex determination in *Ae*. *aegypti* \[[@pgen.1008794.ref017], [@pgen.1008794.ref050]\]. We previously reported that the M locus is surrounded by a large region of reduced recombination between the sex chromosomes, which is associated with sex-specific genetic differentiation and elevated linkage disequilibrium (LD) over about 100 Mb in natural *Ae*. *aegypti* populations \[[@pgen.1008794.ref051]\]. Because statistical power to detect genotype-phenotype associations increases with LD, it is possible that elevated LD may have inflated the proportion of significant genotype-phenotype associations in the centromeric region of chromosome 1. Nevertheless, as mentioned above, comparisons using the same population and the same markers remain valid because any genotyping bias should be consistent across experimental conditions.

The candidate genes that we identified deserve further investigation at the functional level. Although a genetic association does not necessarily imply differential expression, it would be interesting to determine whether candidate genes also display allelic differences in gene expression. Gene knockdown assays could be used to confirm the functional implication of the candidate genes \[[@pgen.1008794.ref052], [@pgen.1008794.ref053]\], although gene knockouts would provide a more definitive answer \[[@pgen.1008794.ref054]\] because they are less prone to false negatives. Mosquito genes uniquely associated with resistance to DENV-3 infection were enriched in genes with zinc ion binding activity, whereas genes associated with resistance to both DENV-1 and DENV-3 infection were enriched in genes with ATP binding activity and sulfur compound transmembrane transporter activity. Zinc is an essential cofactor that ensures the proper folding and functioning of not only cellular proteins but also viral proteins \[[@pgen.1008794.ref055]\]. To our knowledge, there is no prior evidence for a link between zinc ion binding activity and mosquito-virus interactions, however host cellular systems controlling zinc balance are known to interfere with virus replication \[[@pgen.1008794.ref055]\]. Likewise, ATP binding activity and sulfur compound transmembrane transporter activity have not been specifically reported to participate in mosquito-virus interactions, however the high dependence of viruses on the cellular machinery makes any molecular function potentially relevant to host-virus interactions.

Although the forces driving the evolution of DENV resistance in *Ae*. *aegypti* are largely unknown, one evolutionary implication of the distinct gene set underlying resistance to DENV-1 and DENV-3 is that the evolution of resistance to one DENV type is not expected to lead to the correlated evolution of resistance to another DENV type. This finding is consistent with the absence of virus cross-resistance \[[@pgen.1008794.ref056]\] and the lack of genetic trade-offs between the levels of resistance to different viral genotypes \[[@pgen.1008794.ref057]\] in *Drosophila*.

The epidemiological relevance of our results is difficult to assess because dengue epidemiology is poorly documented in Gabon. A recent study reported DENV-3 circulation in 2016--2017 \[[@pgen.1008794.ref058]\] whereas previous dengue outbreaks were mainly associated with DENV-2 in 2007 and in 2010 \[[@pgen.1008794.ref059]\], but this information is insufficient to make a link between the DENV-1 resistance phenotype of the Bakoumba population and the relative lack of this DENV type in recently reported outbreaks in Gabon. In our experiments, we used a DENV-1 isolate from Thailand and a DENV-3 isolate from Gabon but the geographical origin of the virus is unlikely to have influenced the results due to the lack of evidence for DENV local adaptation to *Ae*. *aegypti* populations \[[@pgen.1008794.ref060]\].

In conclusion, our results support a model where the genetic basis of resistance to DENV infection in *Ae*. *aegypti* has a "universal" component that acts across types and strains, and a type- or strain-specific component \[[@pgen.1008794.ref015]--[@pgen.1008794.ref017]\]. In the Bakoumba population, the DENV type-specific component of resistance consists, at least in part, of a distinct set of genes. Our gene enrichment analysis did not identify a functional overlap between the genes uniquely associated with DENV-1 resistance, uniquely associated with DENV-3 resistance, or associated with both. We speculate that *Ae*. *aegypti* resistance to DENV infection may involve different pathways and different molecular mechanisms. Probing this hypothesis will require follow-up studies to functionally test the effect of candidate genes by reverse genetics.

Materials and methods {#sec008}
=====================

Ethics statement {#sec009}
----------------

The Institut Pasteur animal facility has received accreditation from the French Ministry of Agriculture to perform experiments on live animals in compliance with the French and European regulations on care and protection of laboratory animals. This study was approved by the Institutional Animal Care and Use Committee at Institut Pasteur under protocol number 2015--0032.

Cells and virus isolates {#sec010}
------------------------

C6/36 cells (derived from *Ae*. *albopictus*) were cultured in Leibovitz's L-15 medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Life Technologies), 1% non-essential amino acids (Life Technologies) and 0.1% Penicillin-Streptomycin (Life Technologies) at 28°C. DENV-1 isolate KDH0026A was originally obtained in 2010 from the serum of a dengue patient in Kamphaeng Phet, Thailand \[[@pgen.1008794.ref015]\]. DENV-3 isolate GA28-7 was originally obtained in 2010 from the serum of a dengue patient in Moanda, Gabon \[[@pgen.1008794.ref059]\]. Informed consent of the patient was not necessary because viruses isolated in laboratory cell culture are no longer considered human samples. Virus stock was prepared using C6/36 cells, and viral infectious titers were measured on C6/36 cells using a standard focus-forming assay (FFA) as previously described \[[@pgen.1008794.ref061]\].

Mosquito rearing and exposure to DENV {#sec011}
-------------------------------------

All experiments were carried out with *Ae*. *aegypti* mosquito colonies derived from wild populations sampled in Bakoumba, Gabon in 2014, and Cairns, Australia in 2013. Both colonies had been maintained in the laboratory for 8 generations at the time of the experiments. Mosquitoes were reared and exposed to DENV as described previously \[[@pgen.1008794.ref061]\]. Briefly, mosquitoes were reared under standard insectary conditions (28°C ± 1°C, 75 ± 5% relative humidity, 12:12 hour light-dark cycle) with a diet of fish food for larvae (Tetramin), and a 10% sucrose solution for adults. Twenty-four hours before experimental infection with DENV, 5- to 7-day-old female mosquitoes were deprived of sucrose solution. Fresh rabbit erythrocytes were washed and supplemented with ATP at a final concentration of 10 mM to stimulate blood uptake by mosquitoes. The blood meal consisted of a 2:1 mixture of erythrocytes and virus suspension, and was provided for 15 minutes using an artificial membrane feeding system (Hemotek) with pig intestine as a membrane. To expose mosquitoes to different virus concentrations in the dose-response experiments, virus titer in the blood meal was adjusted prior to its preparation by diluting the virus stock in cell culture medium. Aliquots of the blood meal were collected prior to feeding, and viral titers subsequently determined by FFA. Blood-fed females were transferred to 1-pint carton boxes, and kept under controlled conditions (28°C ± 1°C, 70 ± 5% relative humidity, 12:12 hour light-dark cycle) with access to a 10% sucrose solution.

DENV RNA detection {#sec012}
------------------

Mosquito bodies (abdomen and thorax) were ground for two rounds of 30 seconds at 5,000 rpm in a mixer mill (Precellys 24, Bertin Technologies) in 300 μL of squash buffer (10 mM Tris-Hcl pH 8.0, 50 mM NaCl, 1.25 mM EDTA diluted in Ultrapure water) supplemented with Proteinase K (Eurobio-Ingen) at a final concentration of 0.35 g/L. Lysate was heated to 56°C for 5 minutes, and 98°C for 10 minutes. Complementary DNA was synthetized using random hexamers and the M-MLV reverse transcriptase (Life Technologies). Five μL of lysate were included in a 20-μL reaction following the manufacturer's instructions. Finally, a PCR assay using DreamTaq polymerase (Life Technologies), and following manufacturer's instructions was used to generate amplicons from the conserved *NS5* region of DENV-1 (forward 5'-CGAAGATCACTGGTTCAGCA-3'; reverse 5'-ACATCCATCACGGTTCCATT-3') and DENV-3 (forward 5'-AGAAGGAGAAGGACTGCACA-3'; reverse 5'-ATTCTTGTGTCCCAACCGGCT-3'). Representative pictures of the electrophoresis gels and a rationale for scoring RT-PCR readouts are presented in [S2 Fig](#pgen.1008794.s002){ref-type="supplementary-material"}.

Virus titration {#sec013}
---------------

Virus titration was performed by FFA modified from a published protocol \[[@pgen.1008794.ref062]\], as previously described \[[@pgen.1008794.ref061]\]. In brief, a 96-well plate was seeded sub-confluently with C6/36 cells, inoculated with the viral suspension, and covered with an overlay medium containing 1.6% carboxyl methylcellulose solution. After 5 days of incubation at 28°C, cells were fixed using 3.6% formaldehyde. Virus staining was performed using a primary mouse anti-DENV complex monoclonal antibody (MAB8705, Merck Millipore), and a secondary Alexa Fluor 488-conjugated goat anti-mouse antibody (Life Technologies). Infectious foci were counted using a fluorescent microscope and focus-forming units/mL (FFU/mL) subsequently determined.

DNA extraction {#sec014}
--------------

DNA was extracted from individual mosquito heads using a protocol originating from Dr. Pat Roman's laboratory, and adapted from a previous publication \[[@pgen.1008794.ref063]\]. First, the mosquito head was ground during two rounds of 30 seconds at 5,000 rpm in a mixer mill (Precellys 24, Bertin Technologies) in 300 μL of Pat Roman's buffer (0.1 M NaCl, 0.2 M sucrose, 0.1 M Tris-Hcl pH 8.0, 0.05 M EDTA pH 8.0, 0.5% SDS, adjusted at pH 9.2). Lysate was incubated at 65°C for 35 minutes. While still warm, 42.5 μL of 8 M potassium acetate was added to each tube, followed by gentle mixing. After 30 minutes of incubation on ice, lysate was transferred to a new tube and centrifugated for 15 minutes at 12,000 *g*. Supernatant was transferred to a fresh tube, and mixed with 500 μL of 96% ethanol. DNA was left to precipitate overnight at -20°C. Then, tubes were centrifugated for 30 minutes at 12,000 *g*. The pellet was washed once with ice-cold 75% ethanol, and then with ice-cold 96% ethanol, each time followed by 5-minute centrifugation at 12,000 *g*. Finally, the pellet was resuspended in 30 μL of TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0).

Library preparation and sequencing {#sec015}
----------------------------------

The amount of DNA isolated from each head was quantified using the Picogreen (Thermo Fisher Scientific) reagent following the kit protocol. To prepare the 12 sequencing libraries (2 DENV types x 2 phenotypes x 3 replicate experiments), individual DNA samples were combined to obtain 1.0 ng of DNA per pool. Individual DNA concentrations were adjusted prior to pooling so that each individual contributed the same amount of DNA to the pool. Library preparation and exome capture were performed following the detailed Nimblegen SeqCap EZ Library Protocol version 5 provided by Nimblegen (Roche). Briefly, genomic DNA was sheared using a Covaris to around 350-bp fragments and libraries were prepared using the Kapa HTP/LTP (Roche) library preparation kit following kit instructions. At the end of library preparation, the DNA concentration was quantified by Qubit (Thermo Fisher Scientific) and equal amounts of DNA from each library were pooled and allowed to hybridize with the exome-capture probes for 20 hours. Probes targeting the coding DNA sequences (CDS) were designed and synthesized by Nimblegen/Roche following previous studies \[[@pgen.1008794.ref034]--[@pgen.1008794.ref036]\]. Probe design used the AaegL3 genome build of *Ae*. *aegypti* \[[@pgen.1008794.ref028]\] as this was the latest version of the genome at the time of the study. Genome coordinates for probes are provided as the BED file in [S1 File](#pgen.1008794.s005){ref-type="supplementary-material"}. The exome-enriched libraries were sequenced in paired end on an Illumina NextSeq 500 instrument with a high-output v2 kit 300 cycles (Illumina). Raw sequencing data were deposited to the European Nucleotide Archive repository under accession number PRJEB36810.

SNP detection {#sec016}
-------------

Sequencing reads were trimmed and cleaned of adaptor sequences using Trimmomatic \[[@pgen.1008794.ref064]\] before mapping onto the AaegL5 genome assembly using BWA MEM \[[@pgen.1008794.ref065], [@pgen.1008794.ref066]\] The resulting BAM files were further sorted and indexed and PCR duplicate were removed using the SAMtools v1.2 sort, index and rmdup programs, respectively, with default options \[[@pgen.1008794.ref067]\]. The 12 pooled-sequencing BAM files were processed using the mpileup program in SAMtools \[[@pgen.1008794.ref067]\]. Variant calling was performed on the resulting mpileup file using Varscan v2.3.6 \[[@pgen.1008794.ref068]\] with default options except for the minimum coverage threshold (-min-coverage option) set to 10 reads, the variant minor allele frequency threshold (-min-var-freq option) set to 0.01, and the average base quality score threshold (-min-avg-qual option) set to 20. The resulting VCF file was subsequently processed with custom awk scripts to retain only bi-allelic SNPs covered by more than 20 reads and less than 400 reads in each pool. In total, 1,498,923 SNPs were available for association testing with a median coverage ranging from 85X to 149X per pool.

Association testing {#sec017}
-------------------

Exome-wide association testing of the 12 phenotypic pools was performed using the C~2~ contrast statistic implemented in the program BayPass 2.2 \[[@pgen.1008794.ref031], [@pgen.1008794.ref032]\]. This statistic compares allele frequencies between two groups of pools (resistant vs. susceptible), while properly accounting for the overall correlation structure resulting from the shared origin of the pools. Of note, the model implemented in BayPass allows to properly account for the sampling of reads from the (unobserved) allele count data in pooled-sequencing data when estimating and comparing the (unobserved) allele frequencies. Here, the 12 pools originated from the same colony derived from individuals sampled in Bakoumba, Gabon. To improve the statistical power of association tests, a diagonal structure was assumed for the scaled covariance matrix of pool allele frequencies as in the model initially proposed by Nicholson *et al*. \[[@pgen.1008794.ref069]\]. The elements of the diagonal matrix were estimated as described in Gautier *et al*. \[[@pgen.1008794.ref070]\] using the option -*nicholsonprior* newly introduced in version 2.2 of the BayPass program \[[@pgen.1008794.ref031]\]. They can be interpreted as the inverse of the actual effective sample size of the pools and ranged from 2.50% to 14.7% (with a median equal to 3.62%). Three independent runs of BayPass (using the option -seed) were performed to estimate the contrasts for each SNP. The estimated C~2~ values together with the model hyper-parameters were highly correlated across the different runs (e.g., Pearson's correlation \>0.985 for C~2~ values) and only the results from the first BayPass run were retained. Support for association between each SNP and the DENV resistance phenotype was evaluated based on the *p* values derived from the corresponding contrast statistic. The *p*-value distribution was close to uniform except for extremely small *p* values. For each DENV type, gene-specific scores were calculated by adding the estimated C~2~ values of their underlying SNPs. Gene positions were obtained using the base feature annotation file for the AaegL5 genome assembly (available at <https://www.vectorbase.org/organisms/aedes-aegypti>). Using custom awk scripts, a total of 964,398 SNPs (excluding SNPs with a minor allele frequency \<0.05) were assigned to 10,797 different genes with a median number of 62 SNPs per gene (ranging from 1 to 2,377). When a SNP mapped to several genes, it was arbitrarily assigned to only the first ranking one. For each DENV type, support for association of the gene scores with the resistance phenotype was evaluated based on empirical *p* values computed as follows. Let *k* represent the number of SNPs mapping to a given gene *i* and *n*~*k*~ the number of loci of *k* consecutive SNPs (including gene *i*) over the whole genome. Locus-specific scores were calculated as the sum of the *k* C~2~ values estimated for the SNPs underlying the *n*~*k*~ loci. The empirical *p* value of gene *i* was computed as the proportion of the *n*~*k*~ loci with a higher score than the gene *i* score.

Gene enrichment analysis {#sec018}
------------------------

Genes with the highest scores were analyzed for functional enrichment by submitting the gene lists to the DAVID Knowledgebase v6.8 \[[@pgen.1008794.ref071]\]. Enriched terms according to the *Ae*. *aegypti* background were clustered with REVIGO \[[@pgen.1008794.ref072]\]. A treemap for gene ontology (GO) terms enriched in the molecular function category was generated using an in-house R script. In the treemap, each term is represented by a rectangle whose size is proportional to the number of genes in the list out of the total number of genes with similar roles in the *Ae*. *aegypti* genome. Terms with a semantic similarity, e.g. genes with a proximity in the GO graph below 0.7 of similarity, are represented in the same color and the centroid term is emphasized.

Supporting information {#sec019}
======================

###### SNPs associated with DENV-1 and DENV-3 infection in the Bakoumba population.

(**A**) Manhattan plot of *p* values representing the association between SNP frequency and DENV-1 resistance, distributed along the three chromosomes. SNP frequency was compared between phenotypic pools of mosquitoes that are either resistant of susceptible to DENV-1. (**B**) Manhattan plot of *p* values representing the association between SNP frequency and DENV-3 resistance, distributed along the three chromosomes. SNP frequency was compared between phenotypic pools of mosquitoes that are either resistant of susceptible to DENV-3. In (**A**) and (**B**), each dot represents a single SNP and is colored according to the statistical significance of the genotype-phenotype association. Blue dots represent the lower 5% of *p* values and red dots represent the lower 2.5% *p* values. (**C**) Venn diagram of the 0.001% most significant SNPs associated with DENV-1 infection, DENV-3 infection, or both.

(TIF)

###### 

Click here for additional data file.

###### Scoring of the mosquito body infection phenotype.

Photos of representative electrophoresis gels of RT-PCR products for DENV-1 (**A**) and DENV-3 (**B**) detection in mosquito bodies. The readout was based on five scores (exemplified in red font) as follows: 1 = clear and bright band at the right height; 2 = clear and moderately bright band at the right height; 3 = weak band at the right height; 4 = one or several bands at an unexpected height (sometimes accompanied by the right band); 5 = no band. A sample was only considered DENV-positive when its score was 1 or 2. For DENV-1 all five scores were typically present on the gels, whereas for DENV-3 scores 3 and 4 were typically absent. The + and--symbols denote positive and negative controls, respectively.

(TIF)

###### 

Click here for additional data file.

###### List of the 0.001% most significant SNPs associated with DENV-1 infection, DENV-3 infection, or both.

(XLSX)

###### 

Click here for additional data file.

###### List of the 5% most significant genes associated with DENV-1 infection, DENV-3 infection, or both.

(XLSX)

###### 

Click here for additional data file.

###### Exome capture probe design.

(ZIP)

###### 

Click here for additional data file.
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Dear Dr Lambrechts,

Thank you very much for submitting your Research Article entitled \'Exome-wide association study reveals largely distinct gene sets underlying specific resistance to dengue virus type 1 and 3 in Aedes aegypti\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review again a much-revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our [guidelines](http://journals.plos.org/plosgenetics/s/submission-guidelines#loc-materials-and-methods).

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.
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We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Giorgio Sirugo

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The study by Dickson and colleagues report that different sets of genes condition the refractory phenotype of Aedes aegypti to dengue virus (DENV) serotype 1 and 3. The authors conducted exome sequencing of mosquito pools showing differential interaction with the two serotypes, and applied a SNP based association statistics to predict the host genes that likely controlled the observed phenotypes. I find the study interesting but highly intriguing. Here are the problems of this study-

Major Issues

1\. The central hypothesis of this study is that if a vector population responds differentially to two serotypes, then factors associated with the host could explain that phenotypic variation (lines 165-167). But, the observed resistance phenotype could also be due to factors associated with the virus. What was done to rule out that possibility?

2\. The major premise of this study also lack the very fact that genetic changes in the non-coding regions of genome are major contributors of gene regulation. It would make better sense if the authors had sequenced the whole genome, not the exome alone, to identify the associated SNPs. To me, this is a major flaw in the experimental design relative to the said objective of the study.

3\. The authors identified two sets of non-overlapping genes that condition resistance exclusively to DENV1 vs DENV3. To accept that result, it is necessary to provide data that those genes differentially respond to infection with DENV1 vs DENV3. To show that the authors need to provide the expression level of genes, may be in the dissected midguts of the females, after infecting with the two serotypes.

Minor issue

The discussion is largely descriptive. The authors should explain what is the biological meaning of their findings. What are the functional and evolutionary implication that a vector mosquito must utilize non-overlapping gene sets to defend infection by DENV serotypes. Is there an evolutionary benefit for the vector? Is it relevant (the host effect) to differential prevalence of DENV1 relative to DENV3?

Reviewer \#2: Here, the authors have produced a paper investigating the genetic architecture of dengue virus (DENV) resistance in a population of Aedes aegpti from Bakoumba, Gabon. This population displays a stronger resistance phenotype to DENV-1 compared to DENV-3. The authors used experimental bloodmeal exposures and exome sequencing of large phenotypic pools that were either susceptible or resistant. The paper is well written but I believe there are several things that need to be addressed to facilitate understanding by the reader. First, the authors demonstrate that their Bakoumba population of Ae. aegypti have differential susceptibility to DENV-1 vs. DENV-3 and that this is likely the result of mosquito genetic factors because a population of Ae. aegypti from Cairns, Australia were equally susceptible to DENV-1 and DENV-3. While I do not expect the authors to do additional experiments, I do wonder why there was no comparison between the two mosquito populations? This seems like an ideal way to validate susceptibility loci in the Bakoumba population. Second, it would be informative to know DENV epidemiological data for Bakoumba, Gabon. Critically, have there been outbreaks of DENV-1? The authors used a DENV-1 isolate from Thailand for experiments, whereas the DENV-3 isolate was from Gabon. This is somewhat controlled with the Cairns vector competence experiments, but it does raise the question of the appropriateness of the DENV-1 isolate for GxG experiments. Third, as I understand it, exome sequencing was done from mosquito heads only. Given the tissue-specific nature of resistance mechanisms in different host-pathogen combinations, is there potential for information to be missed when not using the whole body?

Reviewer \#3: This is a very interesting and well-written paper investigating how differential SNP frequencies in the exome of an Aedes aegypti population from Gabon (affecting different gene sets) account for variable resistance levels to dengue 1 and dengue 3 viruses. The mosquito population is significantly more resistant to DENV1 than to DENV3. Mosquitoes were exposed to various doses of either virus followed by selection for extremely DENV3 susceptible/resistant versus DENV1 susceptible/resistant phenotypes. Once selected, they were subjected to whole-exome sequencing. Based on computational differential SNP analysis, the authors revealed that resistance to DENV1 in the Gabon population was largely based on different gene sets than resistance to DENV3.

This work is important as it shows on a global level how gene polymorphisms in Ae. aegypti, an organism with a highly complex genome structure, contribute to pathogen resistance phenotypes. The experimental design has been carefully chosen and the data analysis looks thorough.

There are a few important issues that need to be addressed.

Abstract:

Line 38: ....the exomes of.....

Introduction:

Line 96: ...population in the long term....

Line 114: how do you define here strongly resistant versus moderately resistant?

Line 126: ...gene-wide....

Results:

The Results section should be subdivided using sub-headers for the different paragraphs.

Line 189 onwards: This is not very clear to the reader - what does 'individually phenotyped' mean, testing of carcasses via RT-PCR for the presence/absence of virus?? "DNA was extracted from 182, 174, 176 females.....(carcasses/head tissues??); .....combined into 12 standardized phenotypic pools of 30-48 individuals." What does standardized mean here? What individuals? This all should be made more clear using precise descriptions because this information is crucial to understand the experimental design und ultimately the results.

Table 3: "...tested DENV-positive or DENV-negative..."perhaps add here "based on RT-PCR results"

Line 218: is there a reason for using 2 different genome assembly/annotation versions? The analysis still could have been done using version 3 instead of 5? Would this likely/possibly affect the results? A comment here would be helpful.

Additional comment: since virus resistance levels of the "exosome samples" were assessed by RT-PCR, perhaps it would be a good idea to include a representative gel image into the supplemental information showing various PCR amplicons for DENV1 and DENV3 and also positive/negative controls. When a sample was considered negative, was there absolutely no signal at all? What about a very faint signal? How was this classified?

Discussion:

Perhaps also add some discussion points about possible functions of genes with zinc binding activity and those with ATP binding activity / sulfur compound transmembrane transporter activity in the context of mosquito infection with DENV.

Line 288:....about 2% of the entire......

Line 301: ...in genetic ascertainment because for.... (delete 'in').

Line 305: change "Thus" for "This"

Line 312: ....surrounded by a large region.....

Materials and Methods:

Describe, how low and high DENV doses were prepared, validated, and administered to mosquitoes.

Line 345 & 347: replace "derived" for "obtained"

Line 375: .....was synthetized using random hexamers.....5 ul of lysate was included in a 20 ul reaction, following.....

Line 412: this is not clear: ".....equal amounts of DNA from each individual were pooled to reach the required 1.0 ng of DNA required for library preparation." Please re-phrase/clarify.

Figure legends:

Line 702:....at 10 days post....

Figures:

Figure 1 and experiment referring to figure 1: two separate experiments were conducted in which Gabon and Australia mosquitoes were exposed to 3 different infectious doses ranging from 104 to 107 FFU/ml using DENV1 and DENV3. This experimental setup is difficult to retrieve from Fig. 1A. Where/how are the 3 different infectious doses shown? Based on that description, 24 data points should be shown instead of those 22 data points being presented. This is confusing. Perhaps the graph should be separated into two graphs: one for experiment 1 and another one for experiment 2.

Furthermore, the legend, open closed circles for experiment 1 & 2 and large, small circles for different N are way too tiny.

Figure 2: perhaps it would be helpful to extent the figure showing a complete experimental flow chart including number of mosquito carcasses tested for virus titers (FFU/ml), number of replicates, number of head tissues collected, pooling strategy of head tissue samples, and information on sequencing/data analysis strategy.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.
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Dear Dr Lambrechts,

We are pleased to inform you that your manuscript entitled \"Exome-wide association study reveals largely distinct gene sets underlying specific resistance to dengue virus type 1 and 3 in Aedes aegypti\" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plosgenetics@plos.org>.
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Reviewer \#1: The revision is satisfactory.

Reviewer \#2: All of my concerns have been allayed. I believe this now acceptable for publication.

Reviewer \#3: line 202: perhaps change \"The body of\.....was\...\" to plural: Bodies of \...\...were\....
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